The estimated Net Worth of Group Ii, Lp Column Group I... is at least $38.7 Million dollars as of 22 September 2020. Group I owns over 608,000 units of RAPT Therapeutics stock worth over $7,709,715 and over the last 4 years Group sold RAPT stock worth over $31,011,179.
Group has made over 2 trades of the RAPT Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Group sold 608,000 units of RAPT stock worth $18,756,800 on 22 September 2020.
The largest trade Group's ever made was selling 608,000 units of RAPT Therapeutics stock on 22 September 2020 worth over $18,756,800. On average, Group trades about 573,327 units every 18 days since 2020. As of 22 September 2020 Group still owns at least 3,835,679 units of RAPT Therapeutics stock.
You can see the complete history of Group I stock trades at the bottom of the page.
Over the last 5 years, insiders at RAPT Therapeutics have traded over $79,325,123 worth of RAPT Therapeutics stock and bought 4,298,405 units worth $48,553,258 . The most active insiders traders include Peter Svennilson, David V Goeddel, and Fund L.P.Topspin Biotech Fu.... On average, RAPT Therapeutics executives and independent directors trade stock every 11 days with the average trade being worth of $127,774. The most recent stock trade was executed by Dirk G. Brockstedt on 5 January 2024, trading 898 units of RAPT stock currently worth $20,456.
RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company's lead inflammation drug candidate is RPT193 to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. It is also pursuing a range of targets, including general control nonderepressible 2 and hematopoietic progenitor kinase 1 that are in the discovery stage of development. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.
RAPT Therapeutics executives and other stock owners filed with the SEC include: